Abstract
In this work, we review the studies of oxidative stress markers, showing association with the pathophysiology of bipolar disorder (BD). BD is a prevalent, chronic and highly disabling psychiatric disorder. Several hypotheses have been postulated to explain the exact neurochemical mechanisms underlying the pathophysiology of BD, including a role for monoamines, gamma-amino butyric acid (GABA), glutamate, and second messenger singling pathways. More recently, oxidative stress has been implicated in the pathogenesis of BD. Recent studies have reported increased products of lipid peroxidation and alterations of the major antioxidants enzymes in patients with BD. It has been widely demonstrated that the generation of reactive oxygen species (ROS) plays a critical role in the pathophysiology of several neuropsychiatric disorders, such BD.
Similar content being viewed by others
References
Belmaker RH (2004) Bipolar disorder. N Engl J Med 351:476–486
Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet 349:1498–1504
Angst F, Stassen H, Clayton PJ et al (2002) Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord 68:167–181
Carney CP, Jones LS (2006) Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med 68:684–691
Barchana M, Levav I, Lipshitz I, Pugachova I, Kohn R, Wezman A, Grinshpoon A (2008) Enhanced cancer risk among patients with bipolar disorder. J Affect Disord 108:43–48
Levav I, Hohn R, Barchana M, Lipshitz I, Pugachova I, Weizman A, Grinshpoon A (2009) The risk for cancer among patients with schizoaffective disorders. J Affect Disord 114:316–320
Martinez-Aran A, Vieta E, Reinares M et al (2004) Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 161:262–270
Robinson LJ, Thompson JM, Gallagher P et al (2006) A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 93:105–115
Abdalla DS, Monteiro HP, Oliveira JA, Bechara EJ (1986) Activities of superoxide dismutase and glutathione peroxidase in schizophrenia and manic-depressive patients. Clin Chem 32:805–807
Kuloglu M, Ustundag B, Atmaca M, Tezcan AE, Cinkilink N (2002) Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 20:171–175
Ranjekar PK, Hinge A, Hegde MV et al (2003) Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 121:109–122
Ozcan ME, Gulec M, Ozerol E et al (2004) Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 19:89–95
Andreazza AC, Frey BN, Erdtmann B, Salvador M et al (2007) DNA damage in bipolar disorder. Psychiatry Res 153:27–32
Machado-Vieira R, Leke MO, Dietrich V et al (2007) Decreased plasma brain derived neurotrophic factor in unmedicated bipolar patients during maniac episode. Biol Psychiatry 61:142–144
Wang JF, Shao L, Sun X, Young LT (2009) Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 11:523–529
Calabrese V, Scapagnini G, Giuffrida-Stella AM et al (2001) Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem Res 26:739–764
Ben-Schachar D (2002) Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J Neurochem 83:1241–1251
Yumru M, Savas H, Kalenderoglu A, Bulut M, Celik H, Erel O (2009) Oxidative imbalance in bipolar disorder subtypes: a comparative study. Prog Neuropsychopharmacol Biol Psychiatry 33:1070–1074
Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97:1634–1658
Chance B, Sies H, Boveris A (1979) Hydroperoxide metabolism in mammalian organs. Physiol Rev 59:527–605
Floyd RA (1999) Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 222:236–245
Zaleska MM, Floyd RA (1985) Regional lipid peroxidation in rat brain in vitro: possible role of endogenous iron. Neurochem Res 10:397–410
Cochrane CG (1991) Mechanisms of oxidant injury of cells. Mol Aspects Med 12:137–147
De Vasconcelos AP, Bouilleret V, Riban V et al (2005) Role of nitric oxide in cerebral blood flow changes during kainite seizures in mice: genetic and pharmacological approaches. Neurobiol Dis 18:270–281
Kato T, Kato N (2000) Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2:180–190
Mahadik S, Mukherjee S, Scheffer R, Correnti EE, Mahadik JS (1998) Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 43:674–679
Mahadik S, Evans D, Harbans L (2001) Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 25:463–493
Stork C, Renshaw PF (2005) Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 10:900–919
Reddy R, Sahebarao MP, Mukhergee S, Murthy JN (1991) Enzymes the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry 30:109–412
Frey BN, Valvassori SS, Gomes KM et al (2006) Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res 1097:224–229
Frey BN, Martins MR, Petronilho FC et al (2006) Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord 8:275–280
Jayanthi S, Ladenheim B, Cadet JL (1998) Methamphetamine induced changes in antioxidant enzymes and lipid peroxidation in copper/zinc-superoxide dismutase transgenic mice. Ann N Y Acad Sci 844:92–102
Frey BN, Valvassori SS, Réus GZ et al (2006) Changes in antioxidant defense enzymes after d-amphetamine exposure: implications as an animal model of mania. Neurochem Res 31:699–703
Gluck MR, Moy LY, Jayatilleke E et al (2001) Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J Neurochem 79:152–160
Hashimoto K, Shimizu E, Iyo M (2004) Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Rev 24:104–114
Cunha AB, Frey BN, Andreazza AC et al (2006) Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and maniac episodes. Neurosci Lett 398:215–219
Rosa AR, Frey BN, Andreazza AC et al (2006) Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neurosci Lett 47:146–150
Walz JC, Andreazza AC, Frey BN et al (2007) Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder. Neurosci Lett 415:87–89
Walz JC, Frey BN, Andreazza AC et al (2008) Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania. J Psychiatr Res 42:416–421
Kapczinski F, Frey BN, Andreazza AC et al (2008) Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Rev Bras Psiquiatr 30:243–245
Andreazza AC, Kauer-Sant’anna M, Frey BN et al (2008) Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 111:135–144
Kunz M, Gama CS, Andreazza AC et al (2008) Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32:1677–1681
Gsell W, Conrad R, Hicketier M et al (1995) Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of alzheimer type. J Neurochem 64:1216–1223
Andreazza AC, Kapczinski F, Kauer-Sant’Anna M et al (2009) 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci 34:263–271
Cui J, Shao L, Young LT et al (2007) Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 144:47–53
Shao L, Cui J, Young LT et al (2008) The effect of mood stabilizer lithium on expression and activity of glutathione s-transferase isoenzymes. Neuroscience 151:518–524
Marmol F (2008) Lithium: bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium. Prog Neuropsychopharmacol Biol Psychiatry 32:1761–1771
Bakare A, Shao L, Cui J, Young LT et al (2009) Mood stabilizing drugs lamotrigine and olanzapine increase expression and activity of glutathione S-transferase in primary cultured rat cerebral cortical cells. Neurosci Lett 455:70–73
Fukami G, Hashimoto K, Koike K et al (2004) Effect of antioxidant N-acetyl-l-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res 1016:90–95
Valvassori SS, Petronilho FC, Réus GZ et al (2008) Effect of N-acetylcysteine and/or deferoxamine on oxidative stress and hyperactivity in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry 32:1064–1068
Berk M, Copolov DL, Dean O et al (2008) N-acetylcysteine for depressive symptoms in bipolar disorder—a double blind randomized placebo-controlled trial. Biol Psychiatry 64:468–475
Mattiasson G, Shamloo M, Gido G et al (2003) Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nat Med 9:1062–1068
Konradi C, Eaton M, Macdonald ML et al (2004) Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 61:300–308
Jou SH, Chiu NY, Liu CS (2009) Mitochondrial dysfunction and psychiatric disorders. Chang Gung Med J 32:370–379
Kato T, Takahashi S, Shioiri T et al (1993) Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. J Affect Disord 27:53–59
Deicken RF, Weiner MW, Fein G (1995) Decreased temporal lobe phosphomonoesters in bipolar disorder. J Affect Disord 33:195–199
Kato T, Inubushi T, Kato N (1998) Magnetic resonance spectroscopy in affective disorders. J Neuropsychiatry Clin Neurosci 10:133–147
Sun X, Wang JF, Tseng M, Young LT (2006) Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J Psychiatry Neurosci 31:189–196
Marx CE, Stevens RD, Shampine LJ et al (2006) Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology 31:1249–1263
Gerner RH, Post RM, Bunney WE (1976) A dopaminergic mechanism in mania. Am J Psychiatry 133:1177–1180
Falkai P, Wobrock T, Lieberman J et al (2005) Wfsbp task force on treatment guidelines for schizophrenia. World federation of societies of biological psychiatry (wfsbp) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6:132–191
Pantazopoulos H, Stone D, Walsh J et al (2004) Differences in the cellular distribution of D1 receptor mRNA in the hippocampus of bipolars and schizophrenics. Synapse 54:147–155
Vogel M, Pfeifer S, Schaub RT et al (2004) Levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology 50:305–310
Burrows KB, Gudelsky G, Yamamoto BK (2000) Rapid and transient inhibition of mitochondrial function following methamphetamine or 3, 4 methylenedioxymethamphetamine administration. Eur J Pharmacol 398:11–18
Schnyder T, Gross H, Winkler H et al (1991) Crystallization of mitochondrial creatine kinase growing of large protein crystal and electron microscopic investigation of microcrystals consisting of octamers. J Biol Chem 266:5318–5322
Streck EL, Amboni G, Scaini G et al (2008) Brain creatine kinase activity in an animal model of mania. Life Sci 82:424–429
Corrêa C, Amboni G, Assis LC et al (2007) Effects of lithium and valproate on hippocampus citrate synthase activity in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry 31:887–891
El-Mallakh RS, El-Masri MA, Uhf MO et al (2003) Intracerebroventricular administration of ouabain as a model of mania in rats. Bipolar Disord 5:362–365
Li R, El-Mallakh RS, Harrison L et al (1997) Lithium prevents ouabain-induced behavioral changes. Toward an animal model for manic depression. Mol Chem Neuropathol 31:65–72
Decker S, Grider G, Cobb M et al (2000) Open field is more sensitive than automated activity monitor in documenting ouabain-induced hyperlocomotion in the development of an animal model for bipolar illness. Prog Neuropsychopharmacol Biol Psychiatry 24:455–462
Riegel RE, Valvassori SS, Elias G et al (2009) Animal model of mania induced by ouabain: evidence of oxidative stress in submitochondrial particles of the rat brain. Neurochem Int 55:491–495
Wang D, Kreutzer DA, Essigmann JM (1998) Mutagenicity and repair of oxidative DNA damage: insights from studies using defined lesions. Mutat Res 400:99–115
Watt NT, Routledge MN, Wild CP et al (2007) Cellular prion protein protects against reactive-oxygen-species-induced DNA damage. Free Radic Biol Med 43:959–967
El-Khamisy SF, Caldecott KW (2006) TDP1-dependent DNA single-strand break repair and neurodegeneration. Mutagenesis 21:219–224
Emerit I (1994) Reactive oxygen species, chromosome mutation, and cancer: possible role of clastogenic factors in carcinogenesis. Free Radic Biol Med 16:99–109
Faust F, Kassie F, Knasmüller S et al (2004) The use of the alkaline comet assay with lymphocytes in human biomonitoring studies. Mutat Res 566:209–229
Tice RR, Agurell E, Anderson D et al (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206–221
Frey BN, Andreazza AC, Kunz M et al (2007) Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. Prog Neuropsychopharmacol Biol Psychiatry 31:283–285
Andreazza AC, Kauer-Sant’Anna M, Frey BN et al (2008) Effects of mood stabilizers on DNA damage in an animal model of mania. J Psychiatry Neurosci 33:516–524
Buttner N, Bhattacharyya S, Walsh J, Benes FM (2007) DNA fragmentation is increased in non-GABAergic neurons in bipolar disorder but not in schizophrenia. Schizophr Res 93:33–41
Shao L, Young LT, Wang JF (2005) Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 58:879–884
Acknowledgments
The authors would like to thank CNPq, CAPES and UNESC. FD-P and JQ are CNPq Research Fellows. SSV and MM are holders of CAPES studentships, AVS is holder of CNPq Studentships.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Steckert, A.V., Valvassori, S.S., Moretti, M. et al. Role of oxidative stress in the pathophysiology of bipolar disorder. Neurochem Res 35, 1295–1301 (2010). https://doi.org/10.1007/s11064-010-0195-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-010-0195-2